Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment

BACKGROUND: Immunogenicity of cancer vaccines is impacted by adjuvants and schedule, but systematic assessments of their effects have not been performed. Montanide ISA-51, an incomplete Freund’s adjuvant (IFA), is used in many vaccine trials, but concerns have been raised about negative effects in m...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollack, Karlyn E, Meneveau, Max O, Melssen, Marit M, Lynch, Kevin T, Koeppel, Alexander F, Young, Samuel J, Turner, Stephen, Kumar, Pankaj, Sol-Church, Katia, Mauldin, Ileana S, Slingluff Jr, Craig L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213888/
https://www.ncbi.nlm.nih.gov/pubmed/32350119
http://dx.doi.org/10.1136/jitc-2020-000544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213888/
https://www.ncbi.nlm.nih.gov/pubmed/32350119
http://dx.doi.org/10.1136/jitc-2020-000544

Ejemplares similares